For the Inventor, By the Inventor

Enter assignee name

Auckland, New Zealand

Neuren Pharmaceuticals Limited

USPTO Granted Patents = 28

% Expired Patents = 25.0

EPO Patents = 4

Forward Citations = 1,583

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Margaret Anne Brimble (9 out of 21 patents)

Michael John Bickerdike (7 out of 7 patents)

Jian Guan (7 out of 12 patents)

4. Peter David Gluckman (6 out of 29 patents)

5. Frank Sieg (6 out of 9 patents)

6. Lawrence Irwin Glass (5 out of 6 patents)

7. Michael Frederick Snape (5 out of 5 patents)

8. Clive Blower (3 out of 3 patents)

9. James Anthony Bonnar (3 out of 3 patents)

10. James Murray Shaw (3 out of 3 patents)

11. Etienne David Frank Philippe Moniotte (3 out of 3 patents)

12. Martin Bernard Catherine Bousmanne (3 out of 5 patents)

13. Cecilia Betti (3 out of 5 patents)

14. Karel Willy Luc Decroos (3 out of 3 patents)

15. Mimoun Ayoub (3 out of 3 patents)

Core Competencies:

Bicyclic Compounds

Trofinetide

Neuroprotective Compounds

Cognitive Enhancement

Glycyl-L-2-Methylprolyl-L-Glutamate

Neural Regeneration Peptides

Autism Spectrum Disorders

Fragile X Syndrome

Rett Syndrome

Neurodegeneration

Demyelinating Diseases

Cyclic Glycyl-2-Allyl Proline

28 patents: Sort by Forward Citations

1. 12472177 - Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome (2025-11-18),

2. 12297172 - Compositions of trofinetide (2025-05-13),

3. 11866406 - Compositions of trofinetide (2024-01-09),

4. 11370755 - Compositions of trofinetide (2022-06-28),

5. 11197856 - Bicyclic compounds and methods for their use in treating autism (2021-12-14),

6. 10548892 - Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders (2020-02-04),

7. 9867823 - Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders (2018-01-16),

8. 9708366 - Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate (2017-07-18),

9. 9212204 - Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid (2015-12-15),

10. 9119851 - Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals (2015-09-01),

11. 8791117 - Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals (2014-07-29),

12. 8637567 - Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid (2014-01-28),

13. 8138304 - Neural regeneration peptides and formulations thereof (2012-03-20),

14. 8067425 - Neuroprotective bicyclic compounds and methods for their use (2011-11-29),

15. 7887839 - Oral formulations of glycyl-2-methylprolyl-glutamate (2011-02-15),

Company Overview

Neuren Pharmaceuticals Limited is a biopharmaceutical company based in Auckland, New Zealand, focused on developing innovative therapies for neurological disorders. The company specializes in the research and development of novel drug candidates aimed at treating conditions such as autism spectrum disorder and traumatic brain injury. Neuren's approach leverages its expertise in neurobiology to create treatments that address unmet medical needs, with a commitment to improving patient outcomes through advanced therapeutic solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

28 Patents

#13 in Auckland

#23 in New Zealand

#23,285 in the World

Auckland, New Zealand

Neuren Pharmaceuticals Limited

Forward Citations = 1,583

46 inventors:

Margaret Anne Brimble (9 out of 21 patents)

Michael John Bickerdike (7 out of 7 patents)

Jian Guan (7 out of 12 patents)

4. Peter David Gluckman (6 out of 29 patents)

5. Frank Sieg (6 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neuren Pharmaceuticals Limited. Retrieved from https://idiyas.com/company/neuren-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…